Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Swiss Exchange  -  11:30 2022-12-02 am EST
84.14 CHF   +0.05%
12/01European Court Of Justice Issues Landmark Judgments Regarding Trademark Enforcement In Parallel Imports Of Generic Pharmaceuticals : No Repackaging/Rebranding As The Originator Reference Product
AQ
11/30Transcript : Novartis AG - Special Call
CI
11/30Intron Health Lifts Price Target on Novartis, Maintains Buy Recommendation
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVARTIS AG : UBS reiterates its Neutral rating

09/26/2022 | 06:00am EST

In a research note published by Michael Leuchten, UBS gives a Neutral rating to the stock. The target price is revised downwards from CHF 86 to CHF 80.


ę MarketScreener with dpa-AFX Analyser 2022
All news about NOVARTIS AG
12/01European Court Of Justice Issues Lan : No Repackaging/Rebranding As The Originator Referen..
AQ
11/30Transcript : Novartis AG - Special Call
CI
11/30Intron Health Lifts Price Target on Novartis, Maintains Buy Recommendation
MT
11/29AstraZeneca boosts cancer portfolio with $320 mln Neogene deal
RE
11/24Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study f..
AQ
11/23Novartis, Medicines for Malaria Venture to Kick Off Phase 3 Study for Uncomplicated Mal..
MT
11/23Novartis : and Medicines for Malaria Venture announce decision to move to Phase 3 study fo..
PU
11/22Novartis' Sandoz, Teva Pharmaceutical Partner To Expand Biosimilars Production
MT
11/22Generic drugmakers Teva and Sandoz make major push to biosimilars
RE
11/22Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 da..
GL
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2022 51 251 M - -
Net income 2022 8 751 M - -
Net Debt 2022 7 355 M - -
P/E ratio 2022 22,1x
Yield 2022 3,68%
Capitalization 193 B 193 B -
EV / Sales 2022 3,90x
EV / Sales 2023 3,92x
Nbr of Employees 108 000
Free-Float 87,1%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 89,56 $
Average target price 90,72 $
Spread / Average Target 1,29%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Non-Executive Chairman
Shreeram Aradhye Chief Medical Officer
Steffen Lang President-Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG4.81%192 650
JOHNSON & JOHNSON4.57%467 679
ELI LILLY AND COMPANY34.07%356 089
ABBVIE INC.20.87%289 331
NOVO NORDISK A/S22.04%285 887
PFIZER, INC.-13.50%285 774